CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 2,235 enrolled
Drug / intervention
Cell culture derived influenza vaccine +1 morebiological
Likely dose
Cell culture derived influenza vaccine 0.5 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00306527
NCT00306527Phase 3Completed

A Phase III, Observer-Blind, Randomized, Multi-Center Study to Evaluate Safety, Tolerability and Immunogenicity (in a Subset) Following a Single Intramuscular Dose of a Trivalent Subunit Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs, in Healthy Adult and Elderly Subjects Who Received Either One or the Other Vaccine One Year Before in the V58P4 Study.

Novartis Vaccines·interventional·Posted Mar 24, 2006·Updated Aug 14, 2019

In Brief

A Phase 3 clinical trial evaluating Cell culture derived influenza vaccine and egg-derived influenza subunit vaccine for Influenza. Completed, enrolled 2,235 participants across 5 sites.

Detailed Summary

The purpose of the study is to evaluate safety, tolerability and immunogenicity (in a subset) following a dose of a trivalent subunit influenza vaccine produced either in mammalian cells or in embryonated hen eggs, in healthy adult and elderly subjects who received either vaccine one year before (2004) in the study V58P4.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesPoland

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 24, 2006
Enrollment StartSep 1, 2005
Primary CompletionDec 1, 2005
Study CompletionApr 1, 2006
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 20.3 years ago

Interventions

Cell culture derived influenza vaccinebiological

as a single IM injection of 0.5 ml in the deltoid muscle, preferably of the non-dominant arm

egg-derived influenza subunit vaccinebiological

as a single IM injection of 0.5 ml in the deltoid muscle, preferably of the non-dominant arm